Tenet Healthcare stock hits 52-week high at 174.58 USD

Tenet Healthcare Corporation (NYSE:THC)’s stock reached a significant milestone, hitting a 52-week high of 174.58 USD. The healthcare giant, with a market capitalization of $15.67 billion and trailing P/E ratio of 11.12, has earned a "GREAT" financial health rating according to InvestingPro analysis. This achievement reflects a robust performance over the past year, with the stock experiencing a notable 24.55% increase. The healthcare services company, generating $20.52 billion in revenue, has shown resilience and growth, navigating market challenges to reach this peak. Analysts maintain a bullish outlook, with price targets ranging from $154 to $230 per share. Investors have responded positively to the company’s strategic initiatives and operational efficiencies, contributing to its impressive year-over-year change. The recent high underscores Tenet Healthcare’s strong market position and investor confidence in its future prospects. For deeper insights into THC’s valuation and growth potential, access the comprehensive Pro Research Report available exclusively on InvestingPro, along with 10+ additional ProTips and detailed financial metrics.

In other recent news, Tenet Healthcare has experienced several significant developments. S&P Global Ratings upgraded Tenet Healthcare’s credit rating to ’BB-’ from ’B+’, reflecting improved performance and strategic debt reduction. The company has successfully expanded its ambulatory surgery business, which now contributes a notable portion of its revenue. Cantor Fitzgerald maintained its Overweight rating on Tenet Healthcare, citing stability in physician openings and a consistent price target of $177. Meanwhile, BofA Securities raised its price target for the company to $180, maintaining a Buy rating, and highlighting the growth in the Ambulatory Surgery Center business as a key factor. Goldman Sachs also adjusted its outlook, increasing the price target to $154 while keeping a Neutral rating, acknowledging robust fundamentals but noting potential policy risks. Tenet Healthcare held its 2025 Annual Meeting of Shareholders, where all nominated directors were elected, and executive compensation received substantial approval. However, a shareholder proposal on maternal health outcomes did not pass. These developments indicate a period of strategic focus and operational stability for Tenet Healthcare.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.